November 07, 2023
1 min watch
Save
VIDEO: ‘New potential standard-of-care option’ for EGFR exon 20 insertion-mutated NSCLC
MADRID — There were “many exciting updates in EGFR” in the advanced-stage lung cancer setting at ESMO Congress, according to Julia Rotow, MD.
Rotow, clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, discussed positive data from the PAPILLON trial in a video interview. The study showed improvement in clinical outcomes with amivantamab (Rybrevant, Janssen) plus chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced non-small cell lung cancer.
“I think this is a new potential standard-of-care option for this particular patient population in the first-line setting,” she said.
Reference:
- Girard N, et al. Abstract LBA5. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Rotow reports numerous ties to industry.